Venoms

"Venoms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Poisonous animal secretions forming fluid mixtures of many different enzymes, toxins, and other substances. These substances are produced in specialized glands and secreted through specialized delivery systems (nematocysts, spines, fangs, etc.) for disabling prey or predator.

Descriptor ID	D014688
MeSH Number(s)	A12.200.935 D20.888 D23.946.833
Concept/Terms	Venoms Venoms Venom

Below are MeSH descriptors whose meaning is more general than "Venoms".

Anatomy [A]
Fluids and Secretions [A12]
Bodily Secretions [A12.200]
Venoms [A12.200.935]
Chemicals and Drugs [D]
Complex Mixtures [D20]
Venoms [D20.888]
Biological Factors [D23]
Toxins, Biological [D23.946]
Venoms [D23.946.833]

Below are MeSH descriptors whose meaning is more specific than "Venoms".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Venoms" by people in this website by year, and whether "Venoms" was a major or minor topic of these publications.

Bar chart showing 10 publications over 7 distinct years, with a maximum of 4 publications in 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2009	1	0	1
2013	2	2	4
2014	1	0	1
2015	0	1	1
2016	0	1	1
2017	0	1	1
2019	1	0	1

Below are the most recent publications written about "Venoms" by people in Profiles.

Casewell NR, Petras D, Card DC, Suranse V, Mychajliw AM, Richards D, Koludarov I, Albulescu LO, Slagboom J, Hempel BF, Ngum NM, Kennerley RJ, Brocca JL, Whiteley G, Harrison RA, Bolton FMS, Debono J, Vonk FJ, Alf?ldi J, Johnson J, Karlsson EK, Lindblad-Toh K, Mellor IR, S?ssmuth RD, Fry BG, Kuruppu S, Hodgson WC, Kool J, Castoe TA, Barnes I, Sunagar K, Undheim EAB, Turvey ST. Solenodon genome reveals convergent evolution of venom in eulipotyphlan mammals. Proc Natl Acad Sci U S A. 2019 12 17; 116(51):25745-25755.

View in: PubMed
Dai C, Hang Y, Shostak A, Poffenberger G, Hart N, Prasad N, Phillips N, Levy SE, Greiner DL, Shultz LD, Bottino R, Kim SK, Powers AC. Age-dependent human ? cell proliferation induced by glucagon-like peptide 1 and calcineurin signaling. J Clin Invest. 2017 Oct 02; 127(10):3835-3844.

View in: PubMed
Singh S, Wright EE, Kwan AY, Thompson JC, Syed IA, Korol EE, Waser NA, Yu MB, Juneja R. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2017 02; 19(2):228-238.

View in: PubMed
Maruthur NM, Joy SM, Dolan JG, Shihab HM, Singh S. Use of the analytic hierarchy process for medication decision-making in type 2 diabetes. PLoS One. 2015; 10(5):e0126625.

View in: PubMed
Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI. Response to comment on Sarkar et al. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes care 2014;37:666-670. Diabetes Care. 2014 Oct; 37(10):e219-20.

View in: PubMed
Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care. 2014; 37(3):666-70.

View in: PubMed
Viby NE, Isidor MS, Buggeskov KB, Poulsen SS, Hansen JB, Kissow H. Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology. 2013 Dec; 154(12):4503-11.

View in: PubMed
Eberhard CE, Fu A, Reeks C, Screaton RA. CRTC2 is required for ?-cell function and proliferation. Endocrinology. 2013 Jul; 154(7):2308-17.

View in: PubMed
Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013 Apr 08; 173(7):534-9.

View in: PubMed
Rother KI, Spain LM, Wesley RA, Digon BJ, Baron A, Chen K, Nelson P, Dosch HM, Palmer JP, Brooks-Worrell B, Ring M, Harlan DM. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care. 2009 Dec; 32(12):2251-7.

View in: PubMed

People

Explore

Similar Concepts

Top Journals